BSEResult4 Nov 2026 · 4 Nov 2026, 12:08 am
Intimation of the Integrated Unaudited Financial Results for the quarter and half year ended September 30, 2026.
Evonile Pharma Ltd · 500672
✦ AI SummaryResults
Evonile Pharma Ltd has submitted a revised Integrated Filing (Financial) for the quarter and half year ended September 30, 2026, to rectify an inadvertent omission in the heading of a table under 'Disclosure of Outstanding Default on Loans and Debt Securities'. The figures disclosed in the table were correctly stated, but the expression '(INR in crores)' was omitted from the column heading. The amount disclosed against 'Loans/Revolving Facilities like Cash Credit from Banks/Financial Institutions' should be read as ₹800 crores as on September 30, 2026.
Analysis Scores
Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk1/10
Liquidity Impact5/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Evonile Pharma Ltd - 500672 - Intimation Of The Integrated Unaudited Financial Results For The Quarter And Half Year Ended September 30, 2026.
Attachments (1)
📄pdf
Download →
21d91efe-8d62-4535-89ee-ff48cd72c236.pdf
View document text
Evonile Pharma Limited
(formerly known as Novartis India Limited)
November 03, 2026
The Secretary,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001.
Scrip Code: 500672
Sub.: Integrated Filing (Financial) for the Quarter and half year ended September 30, 2026.
Dear Sir/ Madam,
Pursuant to Regulation 10(1A) and other applicable provisions of the SEBI (Listing Obligations and Disclosure
Requirements) Regulations, 2015, read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185
dated December 31, 2024, BSE Circular No. 20250102-4 and NSE Circular No. NSE/CML/2025/02 dated
January 2, 2025, we hereby submit the revised Integrated Filing (Financial) for the quarter and half year ended
September 30, 2026, comprising the Unaudited Financial Statements together with the Limited Review Report
thereon (Annexures I and II) and other disclosures forming part of the said filing.
This revised filing is being submitted solely to rectify an inadvertent omission in the heading of the table
appearing under "Disclosure of Outstanding Default on Loans and Debt Securities" on page 2 of the disclosure
submitted earlier on November 03, 2026, at 7:23 p.m. While the figures disclosed in the table were correctly
stated, the expression "(INR in crores)" was inadvertently omitted from the column heading.
Accordingly, it is clarified that the amount disclosed against "A. Total amount outstanding as on date" under
"Loans/Revolving Facilities like Cash Credit from Banks/Financial Institutions" should be read as ₹800 crores as
on September 30, 2026. Further, the amount disclosed against "Total financial indebtedness of the listed entity
including short-term and long-term debt" should also be read as ₹800 crores.
We confirm that all other disclosures and particulars contained in the earlier submission remain unchanged.
There is no change whatsoever in the Unaudited Financial Results, Limited Review Report, Related Party
Transactions disclosure, or any other information forming part of the Integrated Filing (Financial). This revised
filing is being made solely to correct the aforesaid omission in the table heading.
Kindly take the same on record.
For Evonile Pharma Limited
(Formerly known as Novartis India Limited)
Chandni Maru
Company Secretary & Compliance Officer
A60291
Encl: as above
Registered Office: Inspire BKC, 7th Floor, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra, India.
CIN: L24200MH1947PLC006104 | Tel: +91 22 50243000
Email: investor.relations@evonilepharma.com | Website: www.evonilepharma.com
Evonile Pharma Limited
(formerly known as Novartis India Limited)
Integrated Filing (Financial) for the quarter and half year ended September 30, 2026.
B. Statement on Deviation or Variation for Proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified
Institutions Placement etc.: Not Applicable
C. Disclosure of Outstanding Default on Loans and Debt Securities: - Not Applicable
Sr Particulars Amount
No. (INR in Crores)
1. Loans / revolving facilities like cash credit from banks /
financial institutions
A. Total amount outstanding as on date 800
B. Of the total amount outstanding, amount of default as on Nil
date
2. Unlisted debt securities i.e. NCDs and NCRPS -
A. Total amount outstanding as on date -
B. Of the total amount outstanding, amount of default as on -
date
3. Total financial indebtedness of the listed entity including 800
short-term and long-term debt
D. Disclosure of Related Party Transactions (Applicable only for Half Yearly Filings (i.e. 02nd and 04th
Quarter): Annexure-III
E. Statement on Impact of Audit Qualifications (For Audit Report with Modified Opinion) Submitted Along with
Annual Audited Financial Results (Standalone and Consolidated Separately) (Applicable Only for Annual
Filing i.e. 4th Quarter): Not Applicable
Registered Office: Inspire BKC, 7th Floor, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra, India.
CIN: L24200MH1947PLC006104 | Tel: +91 22 50243000
Email: investor.relations@evonilepharma.com | Website: www.evonilepharma.com
Evonile Pharma Limited
(formerly known as Novartis India Limited)
Annexure III
Value
of the
related Value Value
party Value of of of
transac transacti transac transac
Type of tion as on tion tion
In case amount
related approv during during during
are due to either
Details of the counterparty party ed by the the the
party as a result
transacti the reportin reporti reporti
of the transaction
on audit g period ng ng
Sr. commit QTD period period
No tee/ Sep'26 YTD YTD
Board Sep'26 Jun'26
FY26
Relationship
of the
Openi
counterpart
Name Name y with the
QTD YTD YTD ng Closing
Sep'26 Sep'26 Jun'26 balan balance
listed entity
or its
subsidiary
Novartis Subsidiary Royalty -
AG - Upto 48.76 1.43 9.42 7.99 10.92 -8.48
29th July
2026
Novartis Subsidiary NBS -2.23
Healthcare services 30.00 1.97 7.90 5.92 -2.23
Private
Limited -
Upto 29th
July 2026
Novartis Subsidiary Business
Healthcare support 66.00 20.06 34.67 14.61 -3.05 -25.51
Private services
3 Evonile
Limited - availed
Pharma
Upto 29th
Limited
July 2026
(Formely
known as Novartis Subsidiary Promotio
Novartis Healthcare nal and 12.10 0.74 2.86 2.13 0.81 0.79
4 India Private marketin
Lim ited) Limited - g
Upto 29th services
July 2026
Novartis Subsidiary ESO
Healthcare services 41.00 0.42 6.97 6.55 3.05 0.45
Private provided
Limited -
Upto 29th
July 2026
Subsidiary Employe
Novartis
Healthcare e 5.00 0.35 0.35 - - -0.24
6 balances
Private
transferr
Limited -
Registered Office: Inspire BKC, 7th Floor, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra, India.
CIN: L24200MH1947PLC006104 | Tel: +91 22 50243000
Email: investor.relations@evonilepharma.com | Website: www.evonilepharma.com
Evonile Pharma Limited
(formerly known as Novartis India Limited)
Upto 29th ed –
July 2026 payable
Subsidiary Employe 0.00
Novartis
e 5.00 2.85 2.85 - -
Healthcare
balances
Private
7 transferr
Limited -
ed –
Upto 29th
receivabl
July 2026
Novartis Subsidiary Providen
India t fund 120.00 0.47 2.18 1.70 - -
Limited contributi
Employees' on
Provident
Fund
Novartis Subsidiary Superann
India uation 3.00 - - - - -
9 Limited contributi
Superannu on
ation Fund
Novartis Subsidiary Gratuity 0.00
India fund 23.00 - - - -
10 Limited contributi
Gratuity on
fund
Novartis Subsidiary Purchase -
Pharma of stock 3,000. 97.80 526.57 428.77 293.3 -97.80
11 AG - Upto in trade 00 2
29th July
2026
Novartis- Subsidiary ESOP /
Mitarbeiter ESPP 10.00 - 0.06 0.06 -3.50 -
beteiligung
12 sstiftung
(MBS) -
Upto 29th
July 2026
Tot 3363.86 126.09 593.83 467.74
Registered Office: Inspire BKC, 7th Floor, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra, India.
CIN: L24200MH1947PLC006104 | Tel: +91 22 50243000
Email: investor.relations@evonilepharma.com | Website: www.evonilepharma.com